Cue Biopharma
55 hedge funds and large institutions have $12.8M invested in Cue Biopharma in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 5 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
10% more funds holding
Funds holding: 50 → 55 (+5)
10.04% less ownership
Funds ownership: 28.6% → 18.56% (-10%)
Holders
55
Holding in Top 10
–
Calls
$47K
Puts
$8K
Top Buyers
| 1 | +$134K | |
| 2 | +$92.8K | |
| 3 | +$76.2K | |
| 4 |
BlackRock
New York
|
+$74.1K |
| 5 |
HF
HRT Financial
New York
|
+$53K |
Top Sellers
| 1 | -$1.82M | |
| 2 | -$316K | |
| 3 | -$154K | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$18.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17.3K |